SOX2 & PDL1 Expression on Urinary Bladder Carcinoma
Condition(s):Urinary Bladder NeoplasmLast Updated:June 23, 2022Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Urinary Bladder NeoplasmLast Updated:June 23, 2022Not yet recruiting
Condition(s):Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationLast Updated:February 28, 2024Recruiting
Condition(s):Hepatocellular CarcinomaLast Updated:February 2, 2023Recruiting
Condition(s):Follicular LymphomaLast Updated:February 24, 2021Completed
Condition(s):Progression; SurvivalLast Updated:August 1, 2018Unknown status
Condition(s):Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of the Head and Neck; Esophageal Squamous Cell Carcinoma; Ovarian Neoplasms; Melanoma; Triple Negative Breast Neoplasms; Gastric CancerLast Updated:March 5, 2024Recruiting
Condition(s):Oesophageal Squamous Cell CarcinomaLast Updated:June 14, 2022Recruiting
Condition(s):Metastatic MelanomaLast Updated:September 6, 2022Recruiting
Condition(s):Advanced Lung Carcinoma; Non-small Cell Lung CancerLast Updated:January 8, 2021Not yet recruiting
Condition(s):Lung CancerLast Updated:February 21, 2023Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.